AIMS: There is a perceived benefit associated with the administration of donor lymphocyte infusion (DLI) in patients with lymphoid malignancies relapsing after allogeneic hematopoietic cell transplantation. However, it is unclear if and how this benefit varies according to specific diseases. Because administration of DLI is not universally effective and could be associated with significant toxicities resulting in morbidity and mortality, it is imperative to identify cases where benefits outweigh harms of the procedure. MATERIALS & METHODS: We conducted a systematic review of the published literature and extracted and pooled data independently for each disease cohort: acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL). RESULTS: In summary, 39 studies met inclusion criteria. The pooled proportion (95% CI) for complete response was 27% (16-40) in ALL, 55% (15-92) in CLL, 26% (19-33) in MM, 52% (33-71) in NHL and 37% (20-56) in HL. CONCLUSION: Complete response rates appear higher when DLI is used for relapsed CLL and lymphomas (NHL and HL), and less pronounced in ALL or MM. Absence of data pertaining to disease-specific prognostic determinants, such as adverse genetic or molecular abnormalities, or quantitative disease burden when applicable, limit our ability to identify cases in whom benefits from DLI outweigh risks associated with the procedure within a particular disease.
AIMS: There is a perceived benefit associated with the administration of donor lymphocyte infusion (DLI) in patients with lymphoid malignancies relapsing after allogeneic hematopoietic cell transplantation. However, it is unclear if and how this benefit varies according to specific diseases. Because administration of DLI is not universally effective and could be associated with significant toxicities resulting in morbidity and mortality, it is imperative to identify cases where benefits outweigh harms of the procedure. MATERIALS & METHODS: We conducted a systematic review of the published literature and extracted and pooled data independently for each disease cohort: acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL). RESULTS: In summary, 39 studies met inclusion criteria. The pooled proportion (95% CI) for complete response was 27% (16-40) in ALL, 55% (15-92) in CLL, 26% (19-33) in MM, 52% (33-71) in NHL and 37% (20-56) in HL. CONCLUSION: Complete response rates appear higher when DLI is used for relapsed CLL and lymphomas (NHL and HL), and less pronounced in ALL or MM. Absence of data pertaining to disease-specific prognostic determinants, such as adverse genetic or molecular abnormalities, or quantitative disease burden when applicable, limit our ability to identify cases in whom benefits from DLI outweigh risks associated with the procedure within a particular disease.
Authors: Sarah Nikiforow; Haesook T Kim; Heather Daley; Carol Reynolds; Kyle Thomas Jones; Philippe Armand; Vincent T Ho; Edwin P Alyea; Corey S Cutler; Jerome Ritz; Joseph H Antin; Robert J Soiffer; John Koreth Journal: Haematologica Date: 2016-06-27 Impact factor: 9.941
Authors: J J Scarisbrick; F L Dignan; S Tulpule; E D Gupta; S Kolade; B Shaw; F Evison; G Shah; E Tholouli; G Mufti; A Pagliuca; R Malladi; K Raj Journal: Bone Marrow Transplant Date: 2014-10-13 Impact factor: 5.483
Authors: R Oostvogels; E Kneppers; M C Minnema; R C Doorn; L E Franssen; T Aarts; M E Emmelot; E Spierings; I Slaper-Cortenbach; K Westinga; E Goulmy; H M Lokhorst; T Mutis Journal: Bone Marrow Transplant Date: 2016-11-14 Impact factor: 5.483
Authors: Veronika Bachanova; Linda J Burns; Kwang Woo Ahn; Ginna G Laport; Görgün Akpek; Mohamed A Kharfan-Dabaja; Taiga Nishihori; Edward Agura; Philippe Armand; Samantha M Jaglowski; Mitchell S Cairo; Amanda F Cashen; Jonathon B Cohen; Anita D'Souza; César O Freytes; Robert Peter Gale; Siddhartha Ganguly; Nilanjan Ghosh; Leona A Holmberg; David J Inwards; Abraham S Kanate; Hillard M Lazarus; Adriana K Malone; Reinhold Munker; Alberto Mussetti; Maxim Norkin; Tim D Prestidge; Jacob M Rowe; Prakash Satwani; Tanya Siddiqi; Patrick J Stiff; Basem M William; Baldeep Wirk; David G Maloney; Sonali M Smith; Anna M Sureda; Jeanette Carreras; Mehdi Hamadani Journal: Biol Blood Marrow Transplant Date: 2015-05-14 Impact factor: 5.742
Authors: Julio C Chavez; Mohamed A Kharfan-Dabaja; Jongphil Kim; Binglin Yue; Samir Dalia; Javier Pinilla-Ibarz; Claudio Anasetti; Frederick L Locke Journal: Leuk Res Date: 2014-04-28 Impact factor: 3.156